Ulotaront

DB15665InvestigationalSmall molecule

SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but... SEP-363856 was developed by Sunovion pharmaceuticals.

Chemical structure of Ulotaront
Mechanism
Curator reviewed
Formula / weight
C9H13NOS · 183.27 g/mol (avg)
Code names
SEP-363856 · SEP-856

Resolves to

Compound
UNII3K6270MG59CAS1310426-33-5
Structure
InChIKeyABDDQTDRAHXHOC-QMMMGPOBSA-NSMILESCNC[C@@H]1OCCC2=C1SC=C2
Targets
P08908HTR1AQ96RJ0TAAR1
Transporters
O15244SLC22A2O15245SLC22A1

What you can answer from here — as of September 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
34Drug interactionsStructured to mechanism, not free text
Sign in
13Clinical trialsPhase, status and sponsor resolved per trial
Sign in
21+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ulotaront, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In